Abstract
The major indications for the clinical use of oestrogen and progestogen are oral contraception (OC) in young women, and hormonal replacement therapy (HRT) in menopause. Over the past few years, epidemiological data have associated the use of these hormones to different cardiovascular conditions such as myocardial infarction, cerebrovascular disease and venous thromboembolism. This review summarizes the data discussed and the conclusions achieved by the ESHRE Capri Workshop Group, recently published in Human Reproduction.
Original language | English |
---|---|
Pages (from-to) | 681-687 |
Number of pages | 7 |
Journal | Human Reproduction Update |
Volume | 5 |
Issue number | 6 |
Publication status | Published - Nov 1999 |
Keywords
- Cardiovascular risks
- Hormone replacement
- Oestrogen
- Oral contraception
- Progestogen
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Reproductive Medicine